Maxitrol-suspension-01.jpg (Maxitrol Suspension 01)
Maxitrol Suspension
Product Images NDC 82667-100
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Maxitrol (NDC 82667-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Harrow Eye, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
The Structural Formula For Neomycin Sulfate (Maxitrol Suspension 02)
The Structural Formula For Polymyxin B Sulfate (Maxitrol Suspension 03)
Maxitrol-suspension-04.jpg (Maxitrol Suspension 04)
This is a description for a topical ophthalmic solution called "Maxitrol". It is meant for use in the eyes only. The solution should be stored upright at temperatures between 15°C and 27°C (59°F and 80°F) and should be shaken well before use. The solution contains neomycin sulfate, polymyxin B sulfate, and dexamethasone as active ingredients. The inactive ingredients include banzalkonium chloride, hydrochloric acid and/or sodium hydroxide, hypromellose 2910, polysorbate 20, purified water, and sodium chloride. The solution is manufactured by Harrow Eye, LLC in Nashville, TN, USA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
